AdBio partners

|Portfolio news] We are proud to welcome David Epstein as Chairman of the Board of Agomab ! David is renowned for his transformative leadership in the biopharmaceutical field, having been recognized as one of the top 25 most influential figures in biopharma. David was CEO of Novartis Pharmaceuticals and of Seagen until its acquisition by Pfizer in a $43 billion deal last december. With a track record of over 30 new molecular entities to his name, David's expertise is set to propel Agomab 's mission to develop innovative treatments for fibrotic diseases. This appointment underscores our commitment at AdBio partners to attract international talents to our companies. We believe David’s extensive experience and leadership will be instrumental in helping Agomab 's treatments reach patients. Welcome on board, David! Tim Knotnerus Alain Huriez

[Event] Alain Huriez, Managing Partner d'AdBio partners intervient aujourd'hui au Healthtech Accelerations Summit, à Lyon, lors du panel “Accélérations : les visionnaires ont la parole” à l'occasion des 25 ans de BiotechFinances - Medtech - Santé Numérique - DTx - Intelligence Artificielle. AdBio partners, fonds visionnaire et leader de l’amorçage en France, est au cœur de l’écosystème de l’innovation en santé. Ce sommet est une occasion exceptionnelle d'échanger sur notre mission d’accélération des avancées en santé et de discuter des futures tendances avec d’autres acteurs majeurs du domaine. Merci Jacques-Bernard Taste ! #AdBioImpact #AdBio #biotech #HealthtechSummit #FuturDeLaSanté #anniversaire

[Portfolio news] We’re proud to announce that Augustine Therapeutics has raised a €17 million ($18.5 million) #SeriesA to develop its pipeline for neurodegenerative and cardiometabolic diseases. Warm welcome to our new partners, Asabys Partners, Eli Lilly and Company, and CMT Research Foundation & to Gerhard Koenig, Chairman of the board. Alain Huriez Adrien C. Sylvain Celanire

Nous sommes fiers de dévoiler aujourd’hui un nouveau chapitre du financement de l’innovation en sciences de la vie, le lancement de nos Biotech Studios thématiques, en collaboration avec Inserm Transfert: AndzonBio.    En tant que pionniers de l’investissement d'amorçage en biotechnologie en France, nous ne faisons pas simplement partie de l’écosystème : nous le façonnons.    AndzonBio est une suite de studios thématiques dédiée à accélérer les projets académiques les plus prometteurs, offrant une équipe dédiée et des ressources financières et industrielles, pour développer rapidement ces innovations en startups prêtes à recevoir un financement conséquent. Notre collaboration avec Inserm Transfert, leader européen de la recherche en sciences de la vie, souligne notre engagement à transformer la recherche académique en traitements prometteurs.    Avec AndzonBio, nous élargissons notre offre et comblons le fossé qui existe en Europe entre la recherche académique et le financement d'amorçage. Chez AdBio partners, nous prenons des risques calculés pour que la science issue des laboratoires académiques se transforme en traitements au service des patients.    Le premier studio, AndzonBio1, dédié aux maladies cardiovasculaires, rénales et métaboliques, sera annoncé très prochainement.  ------- Today we are proud to unveil a new chapter in #biotech innovation financing: the launch of our thematic Biotech Venture Studios, in collaboration with Inserm Transfert: AndzonBio. As pioneers of biotech seed investment in France, we’re not just part of the ecosystem; we’re actively shaping it. AndzonBio is a thematic studio suite that will leverage academic excellence, providing a dedicated team, financial and industrial resources to rapidly develop early-stage innovations into startups ready for seed funding. Our collaboration with Inserm Transfert, Europe’s leading player in life sciences research, highlights our commitment to channeling academic excellence into promising treatments. With AndzonBio, we’re expanding our footprint and bridging the gap between academic research and seed funding. We’re embracing calculated risks to ensure promising research coming from the labs becomes treatments addressing patient’s needs. Stay tuned for the announcement of the first start-up studio, AndzonBio1, dedicated to #cardiovascular, renal, and #metabolic diseases. #biotech #studio #venturestudio #seed Alain Huriez, Pascale Auge, Inserm, Didier Samuel, Noémie Pellegrin, Armelle Sérose, Ph.D. Thomas Lombes, Franck Mouthon

[Event] Thumbs up for the European Investment Fund (EIF) who has, over the last 30 years, mobilized over €211 billion of equity financing for Europe’s innovators and risk takers. Thank you for your invaluable support helping us at AdBio partners build the European #Biopharma ecosystem. Meeting some of the greatest entrepreneurs and SMEs that EIF has financed was very inspiring and illustrated Europe’s capacity to innovate in all industries. Great speeches from industry leaders have highlighted the #Megatrends like climate change, energy, social inclusion and of course healthcare, reflecting Europe’s forward-thinking spirit. Thank you Inma Valle, PhD, Sandra FERRI, Anna Finizio, Giada Pellegrin, CFA, Cindy Daniel, Patric Gresko Geoffroy De Ribains

[Event] We are thrilled to announce that AdBio partners will be at the OncoStartup Summit on June 15th. As dedicated supporters of the French #Biotech ecosystem, we are proud to #sponsor this major event focused on pioneering oncology startups. Adrien C., from our team, will serve on the jury, bringing his extensive experience in transforming innovative ideas into clinical realities. Event Highlights: 🔬 A full day dedicated to oncology startups 🎤 39 industry leaders sharing their expertise 💬 Engaging round tables, cross-perspectives, and interviews 🚀 10 standout startups pitching At AdBio partners, we are leaders in #seed financing and company creation in France. We believe in a hands-on approach, working closely with startups to help them reach clinical success. Our role as jury members enables us to offer insights and guidance on this risky preclinical path, helping promising ventures develop needed drugs to cure patients. Thank you OncoSTART for having us! #OncoStartupSummit #InnovationInOncology #SeedFinancing #Startups #Biotech #Medtech #DigitalHealth #Diagnostics #SupportingInnovation #FrenchEcosystem #SummitSponsor

[Portfolio news] We are proud to announce that our portfolio company Agomab has received the Orphan Drug Designation from the FDA for AGMB-447, in Idiopathic Pulmonary Fibrosis (IPF). This milestone illustrates our commitment to nurturing early-stage biotech companies, taking calculated risks, and supporting ventures from academic data through hands-on development, to the clinics. The Agomab journey from seed funding in 2018 to #ODD demonstrates AdBio partners mission to support innovative science with the potential to cure patients. AGMB-447, an inhaled small molecule inhibitor of ALK5, is currently in Phase 1. Congratulations to the team! Alain Huriez Philippe Wiesel Tim Knotnerus #Biotech #Innovation #OrphanDrugDesignation #IPFTreatment #SeedFunding #HealthcareBreakthroughs #AgomabTherapeutics #CureIPF #BiotechInvestment

[Event] 📅 Save the date! Francesc Dosrius Lleonart, Investment Analyst at AdBio partners, will be speaker at the #RESI conference, next Monday in Barcelona. Francesc will be part of the YVC Collective Investor Panel where he will discuss what captures a VC’s interest and how to successfully navigate the venture capital landscape. Get insights on the due diligence process and strategic advice on presenting your business opportunity to maximize investment potential at #RESIBARCELONA Meet the panelists: Francesc Dosrius Lleonart, AdBio partners Anna Bellmunt, Asabys Partners Joana Correia, Aliath Bioventures Cinta Díez, PhD, Invivo Partners Life Science Nation

[AdBio news] We are thrilled to announce that Emma Gasol Escuer, PhD, has been promoted to Partner ! Emma’s extensive experience in the #pharma and #biotech industry, coupled with her strategic and entrepreuneurial mindset, makes her a valuable addition to our leadership team. 📌Emma joined AdBio in 2023, bringing over 20 years of experience in business development, transaction, and innovation management. 👑 Her track record includes a range of transactions from early development to commercial stage, such as in-licensing, co-development, option rights, and acquisitions. 🌐Emma started her career at Crystax Pharma and later joined Gebro, where she led Corporate Development activities. Prior to joining AdBio partners, she was Director of Innovation Scouting at Grifols, demonstrating her ability to drive deal sourcing and identify cutting-edge technologies. Join us in celebrating Emma ! 🙌 #AdBioPartners #BiotechInnovation #LifeSciences #TeamAnnouncement

[Event] 📢 Save the date ! Our Operating Partner and CEO of Orikine Bio, Alejo Chorny, will be speaker at RESI Europe 2024 on June 17 in #Barcelona. This hybrid conference features an in-person event on June 17 and online partnering sessions on June 18-19. Alejo will be a panelist on the Early Stage Therapeutics Panel, sharing insights on investor strategies for #sourcing and evaluating new therapeutic technologies, and discussing how #investors collaborate with #startups to bring new drugs to market. As a key player in Spain and Europe's biotech ecosystem, we are thrilled to be part of this dynamic conversation. Don't miss the opportunity to engage with industry leaders and innovators! Life Science Nation #RESIEurope2024 #Biotech #VentureCapital #Innovation #Therapeutics #InvestingInTheFuture